<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132050</url>
  </required_header>
  <id_info>
    <org_study_id>R788-1301</org_study_id>
    <nct_id>NCT04132050</nct_id>
  </id_info>
  <brief_title>A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788</brief_title>
  <official_title>A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788
      compared with placebo, and to investigate the safety and efficacy of long term dosing of R788
      in patients with chronic idiopathic thrombocytopenic purpura.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with stable platelet response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients with a stable platelet response by Week 24 defined as a platelet count of ≥ 50000/μL on at least 4 of 6 visits between Week 14 to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with overall response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of patients with a platelet count ≥50000/μL on at least 1 of 6 visits from Week 2 to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of maintained platelet count</measure>
    <time_frame>52 weeks</time_frame>
    <description>Duration of maintained platelet count since first achievement of a platelet count ≥50000/μL after administration of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a platelet count ≥50000/μL</measure>
    <time_frame>Every 2 weeks up to Week 24, every 4 weeks up to Week 52 and every 8 weeks up to 3 years</time_frame>
    <description>Percentage of patients with a platelet count ≥50000/μL at the specified evaluation time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a platelet count increase ≥20000/μL above baseline and ≥30000/μL</measure>
    <time_frame>Every 2 weeks up to Week 24, every 4 weeks up to Week 52 and every 8 weeks up to 3 years</time_frame>
    <description>Percentage of patients with a platelet count increase ≥20000/μL above baseline and ≥30000/μL at the specified evaluation time point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>R788</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are administered R788 for 24 weeks (double-blind period), followed by R788 for up to 52 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are administered Placebo for 24 weeks (double-blind period), followed by R788 for up to 28 weeks (open-label period). Patients who have completed open-label period and meet the criteria are eligible to continue R788 treatment over a 3 year period (extension - period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R788</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>R788</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients

          -  Patients diagnosed with idiopathic thrombocytopenic purpura at least 6 months before
             acquisition of consent

          -  Patients with a platelet count averages &lt;30000/μL during screening period. Each
             platelet count should not exceed 35000/μL.

          -  Patients who have used and failed or who were intolerant at least 1 typical regimen
             for the treatment of ITP before informed consent (with or without splenectomy)

        Exclusion Criteria:

          -  Patients with thrombocytopenia associated with other disease

          -  Patients with autoimmune hemolytic anemia

          -  Patients with poorly controlled hypertension

          -  Patients with a history or active coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Koshihara</last_name>
    <role>Study Director</role>
    <affiliation>Kissei Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kissei Pharmaceutical Co., Ltd.</last_name>
    <phone>Email only</phone>
    <email>rinsyousiken@pharm.kissei.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo And Other Cities In Japan</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

